Comparison of DNA and mRNA vaccines against cancer

Area of Science:

• Oncology
• Immunology
• Vaccinology

Background:

• Nucleic acid vaccines (NAVs), including DNA and mRNA types, deliver genetic information for tumor antigens (TAs) to induce anti-cancer immune responses.
• Despite manufacturing advantages (ease, safety, simplicity), NAVs face challenges including TA selection, insufficient immunogenicity, and the tumor microenvironment's immunosuppressive effects.
• NAVs are not yet considered superior alternatives to traditional peptide vaccines for cancer treatment.

Purpose of the Study:

• To review and discuss current strategies aimed at improving the efficacy of nucleic acid vaccines for cancer therapy.
• To address the limitations hindering the widespread adoption of NAVs in oncology.
• To highlight advancements in overcoming challenges associated with anticancer NAV development.

Main Methods:

• Literature review of existing research on nucleic acid vaccine development for cancer.
• Analysis of strategies employed to enhance immunogenicity and overcome immunosuppression.
• Discussion of approaches for optimizing tumor antigen selection in NAV design.

Main Results:

• Various methods have been investigated to boost the immune response generated by NAVs.
• Strategies focus on improving antigen presentation, delivery systems, and overcoming tumor-induced immune evasion.
• Progress has been made in enhancing the potential of NAVs as a viable cancer treatment modality.

Conclusions:

• Improving TA selection and enhancing immunogenicity are critical for successful anticancer NAVs.
• Overcoming the immunosuppressive tumor microenvironment is essential for effective cancer immunotherapy with NAVs.
• Further research and development are needed to establish NAVs as a leading cancer therapy.